Definium Therapeutics (NASDAQ:DFTX) Shares Down 7.7% – What’s Next?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price was down 7.7% during trading on Friday . The stock traded as low as $44.73 and last traded at $44.74. Approximately 391,925 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 2,324,419 shares. The stock had previously closed at $48.45.

Analyst Ratings Changes

A number of analysts have weighed in on DFTX shares. Stifel Nicolaus boosted their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC increased their price target on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Finally, JonesTrading upped their target price on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $49.23.

Definium Therapeutics Price Performance

The stock has a market cap of $4.56 billion, a P/E ratio of -18.37 and a beta of 2.20. The company’s 50 day moving average price is $28.68 and its 200-day moving average price is $21.50. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, sell-side analysts expect that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock valued at $2,165,763 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Institutional Trading of Definium Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DFTX. Cerity Partners LLC raised its holdings in Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after purchasing an additional 1,165 shares during the last quarter. Creative Planning boosted its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. Bay Rivers Group boosted its stake in shares of Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its position in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after buying an additional 2,079 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.